The EPHOR project aims to develop a working life exposome toolbox that can be used for evidence-based and cost-effective prevention by scientists, occupational health practitioners, and policy makers. We will develop methods and tools to characterise the working life exposome to obtain a better and more complete knowledge of it. Through uniquely combining large-scale pooling of existing data (>40 cohorts; ~ 21 million people) systematically looking at many types of exposure and diseases with the collection of new data in case studies in which we will investigate the effects of working-life exposure on respiratory health in the general population and night shift workers.
LifeGlimmer is responsible for the bioinformatics analysis of the omics data, including the analysis of adverse outcome pathways (AOPs) and exposome stratification. In addition, we are involved in the establishment of the data management and analytics platform and, in particular, in the visualisation of AOPs in the envisaged Exposome Toolbox.
PerICo is a multi-partner European Training Network under the European Union programme Horizon 2020. PerICo aims at uncovering how peroxisomes, important cellular organelles, participate in the intricate cellular interaction and signalling network. In light of the current understanding of the central role of peroxisomes in a variety of metabolic diseases, cancer and aging – this timely research programme will benefit society. PerICotrains a new generation of highly-qualified ESRs (Early stage researchers) focusing on the identification and functional characterization of peroxisomal membrane contact-sites and transporters.
Research at LifeGlimmer will specifically contribute to the model-driven discovery and network modelling of peroxisomal interactions.
The PERAID project proposes to implement personalized medicine (PM) in severe infectious diseases, specifically focusing on the life-threatening necrotizing soft tissue infections (NSTI) as well as the large heterogeneous group of sepsis patients that represent a global health priority. Personalized medicine is a neglected, albeit much desired, development in the field of acute infectious diseases. The patient population is highly heterogeneous with different pathogens, pathogenic mechanisms, as well as varying predisposing host factors, and importantly, a dysregulated host response to infection is directly linked to severity and outcome of severe infections, i.e. sepsis and NSTI. Hence, tailored immunotherapy in stratified patients holds great potential. PERAID builds on the advances and resources created in the EU FP7-project INFECT, including the world’s largest patient cohort on NSTI (Scandinavian patients enrolled by PERAID’s partners), biobank, multi-omics data, and pathophysiologic models. These already available resources combined with an extended Nordic consortium enables PERAID to advance to the next phase of implementing PM in NSTI as well as extending the efforts into the sepsis field.
LifeGlimmer contributes by developing tools that support clinical decision making in treatment of NSTI and sepsis patients.
TranSYS, coordinated by K. Van Steen (KU Leuven), will recruit 15 ESRs (Early Stage Researchers) to highly skilled jobs in the new area of Systems Health developing tools and approaches to exploit large and complex datasets, to advance Precision (Personalised) Medicine in several disease areas. The training programme and experience of different international research environments cuts across traditional data and life sciences silos. The emphasis on translational research will support new collaborations between academics and the pharma and health analytics sectors. Our ESR projects will advance the state of the art on biomarker discovery, improve understanding of disease-specific molecular mechanism and target identification for optimal diagnostics, disease risk and treatment management, refine data generation and their management (including warehousing, disease specific and standardised approaches for data processing, visualisation and model development) leading to improved clinical study design, clinical sampling and more targeted therapeutics. This ETN (European Training Network) will internationalise participants, and leverage EC (European Commission) and industry sponsorship, to structure and expand the unique training programme and advance emerging research areas, combining wet-lab, clinical and Big Data resources with computational and modelling know-how.
Focus of LifeGlimmer is on developing and demonstrating data mining and A.I. tools to better understand patient heterogeneity and assist patient stratification.
The goal of PERMIT is to establish personalised medicine in severe infectious diseases, specifically for necrotizing soft tissue infections as well as sepsis. Focus lies on the improvement of diagnosis and therapy predominantly based on the integration of diverse data sources and the derivation of a more precise risk assessment..
LifeGlimmer provides computational analysis of omics data as well as the establishment of decision support system for personalised treatment of NSTI patients.
The overarching aim of IBISBA is to create a coordinated network of research infrastructure facilities and thus provide a novel and timely response to the main challenges that are currently hampering the development of industrial biotechnology (IB) as a key enabling technology of Europe’s bioeconomy.
Building upon its expertise in large-scale functional annotation, analysis and integration of heterogeneous data sets (in particular omics), semantic technologies and metabolic modeling, Lifeglimmer participates in various WPs, in particular on the development and deployment of computational workflows for biocatalyst and process design, semantic analysis and integration of data using a decision support system.